KPRX Kiora Pharmaceuticals

Kiora In-Licenses KIO-401 (mitucapistat) from Senju for CRAO and NAION

Kiora obtained exclusive ex-Asia rights to the oral calpain inhibitor KIO-401 (mitucapistat), which completed Phase 2 and Phase 3 trials in CRAO in Japan showing visual acuity gains. The company plans to initiate a multinational Phase 3 registration trial in CRAO targeted for 2027 and a Phase 2b trial in NAION targeted for 2028.

Kiora licenses KIO-301 South Korea rights to Chong Kun Dang

Kiora granted CKD exclusive development and commercialization rights for KIO-301 in South Korea in exchange for a $1 million upfront payment plus future milestones and royalties. CKD will lead all local activities and will join Kiora’s existing partners (Théa, Senju) to coordinate a single global Phase 3 trial in retinitis pigmentosa. The deal completes Kiora’s major-market partnering strategy for KIO-301, freeing internal resources to advance KIO-104 and non-ophthalmic programs.